• OVERVIEW
• ABOUT VERISTRAT
  • TREATING NSCLC
  • CLINICAL DATA
  • CLINICAL DEVELOPMENT
  • PUBLICATIONS
• USING VERISTRAT
• REIMBURSEMENT
• FAQS

Publications

• VeriStrat Classifier for Survival and Time To Progression in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Erlotinib and Bevacizumab. Lung Cancer, September 2010, Carbone et al.
• Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503. Journal of Thoracic Oncology, February 2010, Amann et al.

• Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer, Epidemiology, Biomarkers and Prevention, February 2010, Chung et al.

• Mass Spectrometry to Classify Non-Small Cell Lung Cancer Patients for Clinical Outcome After
  Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort
  Cross-Institutional Study. Journal of the National Cancer Institute, June 2007, Taguchi et al.

2011 ASCO Abstracts

• PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC).

2010 ASCO Abstracts

• Bevacizumab/erlotinib (BEER) as first-line treatment for untreated advanced non-squamous non-small cell lung cancer (NSNSCLC).

2009 ASCO Abstracts

• Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma.
• Genetic and proteomic features associated with survival after treatment with erlotinib in first line therapy of non-small cell lung cancer.

2008 ASCO Abstracts

• Changes in serum proteomic profile of non-small cell lung cancer (NSCLC) patients during therapy with epidermal growth factor receptor tirosine kinase inhibitors (EGFR-TKIs): Preliminary report.
• Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone.